Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Fatal Progression of Mutated TP53-Associated Clonal Hematopoiesis following Anti-CD19 CAR-T Cell Therapy.

Current oncology (Toronto, Ont.) - 13 Jan 2023

Eder Lea Naomi, Martinovic Danilo, Mazzeo Paolo, Ganster Christina, Hasenkamp Justin, Thomson Julia, Trummer Arne, Haase Detlef, Wulf Gerald

Abstract excerpt

We present the case of a 64-year-old man diagnosed with large B-cell lymphoma who relapsed twice after standard-of-care therapy. Due to persisting cytopenia, Next generation sequencing analysis was performed, revealing a small TP53-mutated clone. As a third-line therapy, the patient was treated with CAR-T cells, which resulted in complete remission. However, this treatment also led to the expansion of the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antigens, CD19
Share to Cell- and Tissue-Based Therapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Clonal Hematopoiesis

Share to Immunotherapy, Adoptive

Share to Mutation

Share to Receptors, Chimeric Antigen

Share to Remission Induction

Share to Tumor Suppressor Protein p53

Source

Open in PubMed Open full text

Identifiers

PMID: 36661736
DOI: 10.3390/curroncol30010087
PMCID: PMC9858310

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Fatal Progression of Mutated TP53-Associated Clonal Hematopoiesis following Anti-CD19 CAR-T Cell Therapy.PMID 36661736Read ↗

Genetic alterations crossing the borders of distinct hematopoetic lineages and solid tumors: Diagnostic challenges in the era of high-throughput sequencing in hemato-oncology.Semantic proximity Read ↗

CAR19 therapy drives expansion of clonal hematopoiesis and associated cytopeniasSemantic proximity Read ↗

Impact of TP53 Genomic Alterations in Large B-Cell Lymphoma Treated With CD19-Chimeric Antigen Receptor T-Cell Therapy.Semantic proximity Read ↗

Impact of TP53 mutations on survival outcomes in the CAR-T era of large B-cell lymphoma.Semantic proximity Read ↗

Clinical Implications and Dynamics of Clonal Hematopoiesis in Anti-CD19 CAR T-cell Treated PatientsSemantic proximity Read ↗

Clonal hematopoiesis is associated with increased toxicity in large B-cell lymphoma patients treated with chimeric antigen receptor T cell therapySemantic proximity Read ↗

TP53 mutations are early events in chronic lymphocytic leukemia disease progression and precede evolution to complex karyotypes.Semantic proximity Read ↗

Low-burden TP53 mutations in CLL: clinical impact and clonal evolution within the context of different treatment options.Semantic proximity Read ↗

Therapy-related clonal cytopenia as a precursor to therapy-related myeloid neoplasms.Semantic proximity Read ↗

Idelalisib-rituximab induces durable remissions in TP53 disrupted B-PLL but results in significant toxicity: updated results of the UK-wide compassionate use programme.Semantic proximity Read ↗

Role of TP53 mutations in the origin and evolution of therapy-related acute myeloid leukaemia.Semantic proximity Read ↗

CAR T-cell therapy for a relapsed/refractory acute B-cell lymphoblastic lymphoma patient in the context of Li-Fraumeni syndrome.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.